Loading stock data…
Entera Bio Ltd (ENTX)
$1.65+0.02 (+1.23%)
After Hours$1.58-0.07 (-4.24%)· Last close Jun 29
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Entera Bio Ltd. in the Healthcare sector is trading at $1.65 with a market capitalization of $58M. Wall Street consensus targets $9.00 (1 analysts), implying a +445.5% move over the next 12 months. The stock is currently 49% below its 52-week high of $3.22, remaining 2.4% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 76 is overbought against a weak tape. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +445.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 76 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0↓ | $42,000 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$3.54M↓ | -$3.04M↑ | -$3.26M↓ | -$2.67M↓ | -$2.56M |
| Net Income | -$3.50M↓ | -$3.02M↑ | -$3.20M↓ | -$2.66M↓ | -$2.57M |
Peer Comparison
JNJUNHPFE
Fundamentals
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$58.41M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-115.81%
Volume
Today's trading volume
471,029
Recent News
ENTX Stock On Track For Best Day In Over 5 Years — What’s Driving The Rally?
Entera said that the FDA backed its plan for a single large late-stage clinical trial of its experimental once-daily pill, EB613, for postmenopausal women with osteoporosis.
Entera Bio (ENTX) Upgraded to Buy: Here's What You Should Know
Entera Bio (ENTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Entera Bio Touts EB613 Oral Anabolic Tablet as Osteoporosis Care Gap Persists, Phase III Near
Entera Bio (NASDAQ:ENTX) executives and physician panelists used a roundtable discussion to highlight what they described as persistent gaps in osteoporosis care and the potential role for the company’s lead candidate, EB613, which it is developing as an oral anabolic (bone-forming) tablet. Miranda
Opko Health Inc. (OPK) Builds Value Through Partnerships and Innovation
Opko Health Inc. (NASDAQ:OPK) is one of the best high-return penny stocks to buy right now. On February 10, analysts at H.C. Wainwright reiterated a Buy rating on Opko Health Inc. (NASDAQ:OPK) and settled on a $3 price target. The positive stance underscores the research firm’s confidence amid progress in the company’s biological partnerships. The […]
Opko Health (OPK) Expands Entera Partnership for Drug Co-Development
Opko Health Inc. (NASDAQ:OPK) is one of the best stocks under $3 to invest in. On February 4, Opko Health Inc. (NASDAQ:OPK) announced it expanded its partnership with Entera Bio Ltd., a company developing oral peptide and protein replacement therapies, to advance the first oral long-acting PTH analog (LA-PTH) treatment for patients with hypoparathyroidism, in […]